Next Article in Journal
Murine Falcor/LL35 lncRNA Contributes to Glucose and Lipid Metabolism In Vitro and In Vivo
Previous Article in Journal
C-Reactive Protein and Serum Albumin Ratio: A Feasible Prognostic Marker in Hospitalized Patients with COVID-19
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 10
Issue 6
10.3390/biomedicines10061395
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Biomedicines 2021, 9(11), 1713.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Karakus et al. Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult. Biomedicines 2021, 9, 1713

by
Ozlem Ozen Karakus
1,
Noureldien H. E. Darwish
1,2,
Thangirala Sudha
1,
Taher A. Salaheldin
1,
Kazutoshi Fujioka
1,
Peter C. Taylor Dickinson
3,
Brian Weil
4,5 and
Shaker A. Mousa
1,*
1
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY 12144, USA
2
Clinical Pathology (Hematology Section), Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
3
Pro-Al Medico Technologies Inc., Suffern, NY 10901, USA
4
Departments of Physiology & Biophysics, School of Medicine & Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, USA
5
VA WNY Healthcare System, Buffalo, NY 14215, USA
*
Author to whom correspondence should be addressed.
Biomedicines 2022, 10(6), 1395; https://doi.org/10.3390/biomedicines10061395
Submission received: 8 June 2022 / Accepted: 8 June 2022 / Published: 13 June 2022
(This article belongs to the Section Nanomedicine and Nanobiology)
Browse Figure
Versions Notes
In the published manuscript [1] in the Results section, in the subsection titled 3.5. Cardioprotective Effects of T3 and PLGA-T3/PCr NPs under Hypoxia, in Figure 6A there was an unintentional mistake of an overlap in Figures under different treatment conditions while taking photographs/labeling at a lower magnification. Experiment was repeated and photographs were taken under higher magnification for improved image quality. The scientific conclusion was unaffected and there is no change in the legend of the figure. The published figure is replaced with the new Figure 6A.
The authors apologize for any inconvenience. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Karakus, O.O.; Darwish, N.H.E.; Sudha, T.; Salaheldin, T.A.; Fujioka, K.; Dickinson, P.C.T.; Weil, B.; Mousa, S.A. Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult. Biomedicines 2021, 9, 1713. [Google Scholar] [CrossRef] [PubMed]
Biomedicines 10 01395 g001 550
Figure 6. Expression of troponin T in neonatal cardiomyocytes under hypoxic condition. (A) Immunostaining by anti-troponin T-PE (confocal microscopy). (B) Quantitation of troponin T in neonatal cardiomyocyte and in medium. ** p < 0.05, *** p < 0.001 versus untreated control, with full reversal and improvement versus control under normoxic condition. These results suggest that PLGA-T3 NPs and PLGA-T3 NPs/PCr inhibit the damaging effect of hypoxia on cardiomyocytes.
Figure 6. Expression of troponin T in neonatal cardiomyocytes under hypoxic condition. (A) Immunostaining by anti-troponin T-PE (confocal microscopy). (B) Quantitation of troponin T in neonatal cardiomyocyte and in medium. ** p < 0.05, *** p < 0.001 versus untreated control, with full reversal and improvement versus control under normoxic condition. These results suggest that PLGA-T3 NPs and PLGA-T3 NPs/PCr inhibit the damaging effect of hypoxia on cardiomyocytes.
Biomedicines 10 01395 g001
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Karakus, O.O.; Darwish, N.H.E.; Sudha, T.; Salaheldin, T.A.; Fujioka, K.; Dickinson, P.C.T.; Weil, B.; Mousa, S.A. Correction: Karakus et al. Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult. Biomedicines 2021, 9, 1713. Biomedicines 2022, 10, 1395. https://doi.org/10.3390/biomedicines10061395

AMA Style

Karakus OO, Darwish NHE, Sudha T, Salaheldin TA, Fujioka K, Dickinson PCT, Weil B, Mousa SA. Correction: Karakus et al. Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult. Biomedicines 2021, 9, 1713. Biomedicines. 2022; 10(6):1395. https://doi.org/10.3390/biomedicines10061395

Chicago/Turabian Style

Karakus, Ozlem Ozen, Noureldien H. E. Darwish, Thangirala Sudha, Taher A. Salaheldin, Kazutoshi Fujioka, Peter C. Taylor Dickinson, Brian Weil, and Shaker A. Mousa. 2022. "Correction: Karakus et al. Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult. Biomedicines 2021, 9, 1713" Biomedicines 10, no. 6: 1395. https://doi.org/10.3390/biomedicines10061395

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop